Molecular targeted therapy of gynecological malignant tumors: the development and challenge, from laboratory to clinic
- First Online:
- 57 Downloads
More and more molecular drugs based on targeted therapy have been utilized in the treatment of gynecologic cancer, especially in ovarian cancer. In this article, we systematically review the current targeted therapeutic trials running in clinic. Large, randomized trials have been conducted in the treatment of ovarian cancer, endometrial cancer and cervical cancer by usingsmall molecule, antisense, mutational gene as well as antibodies. Other planned or ongoing trials currently targeted at molecular markers which may play important roles in gynecological carcinogenesis and progression suggest that combination chemotherapy with molecular targeted therapy will ultimately be an important option.
Keywordstarget therapy gynecologic malignant tumors clinical trail molecular medicine
Unable to display preview. Download preview PDF.
- 26.Mizuki M, Ueda S, Matsumura I, Ishiko J, Schwable J, Serve H, Kanakura Y. Oncogenic receptor tyrosine kinase in leukemia. Cell Mol Biol (Noisy-le-grand), 2003, 49(6): 907–922Google Scholar
- 34.Schilder R J, Sill M W, Chen X, Darcy K M, Decesare S L, Lewandowski G, Lee R B, Arciero C A, Wu H, Godwin A K. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res, 2005, 11(15): 5539–5548PubMedCrossRefGoogle Scholar
- 35.Gordon A N, Finkler N, Edwards R P, Garcia A A, Crozier M, Irwin D H, Barrett E. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer, 2005, 15(5): 785–792PubMedCrossRefGoogle Scholar
- 39.Bookman M A, Darcy K M, Clarke-Pearson D, Boothby R A, Horowitz I R. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol, 2003, 21(2): 283–290PubMedCrossRefGoogle Scholar
- 41.Oza A M, Elit L, Swenerton K, Faught W, Ghatage P, Carey M, McIntosh L, Dorr A, Holmlund J T, Eisenhauer E. Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116). Gynecol Oncol, 2003, 89(1): 129–133PubMedCrossRefGoogle Scholar
- 42.Advani R, Peethambaram P, Lum B L, Fisher G A, Hartmann L, Long H J, Halsey J, Holmlund J T, Dorr A, Sikic B I. A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. Cancer, 2004, 100(2): 321–326PubMedCrossRefGoogle Scholar
- 48.Hortobagyi G N, Ueno N T, Xia W, Zhang S, Wolf J K, Putnam J B, Weiden P L, Willey J S, Carey M, Branham D L, Payne J Y, Tucker S D, Bartholomeusz C, Kilbourn R G, De Jager R L, Sneige N, Katz R L, Anklesaria P, Ibrahim N K, Murray J L, Theriault R L, Valero V, Gershenson D M, Bevers M W, Huang L, Lopez-Berestein G, Hung M C. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol, 2001, 19 (14): 3422–3433PubMedGoogle Scholar
- 49.Kavanagh J J, Gershenson DM, Choi H, Lewis L, Patel K, Brown G L, Garcia A, Spriggs D R. Multi-institutional phase 2 study of TLK286 (TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer. Int J Gynecol Cancer, 2005, 15(4): 593–600PubMedCrossRefGoogle Scholar
- 50.Vasey P A, Shulman L N, Campos S, Davis J, Gore M, Johnston S, Kirn D H, O’Neill V, Siddiqui N, Seiden M V, Kaye S B. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol, 2002, 20(6): 1562–1569PubMedCrossRefGoogle Scholar